Quince Therapeutics, Inc. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
Quince Therapeutics, Inc. (QNCX) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $6.36 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-05-11
- Quince Therapeutics, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2026-03-31 was $6.36M.
- Quince Therapeutics, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-03-31 was $0.00.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month |
|---|---|
| 2026-03-31 | $6.36M 10-Q · filed 2026-05-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |